Clinical trial
Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2…
NCT00102297 · Kyntra Bio, Industry · Completed
Key facts
| NCT number | NCT00102297 |
|---|---|
| Title | Study of the Safety of FG-3019 in Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus |
| Official title | A Phase 1 Study of the Safety, Pharmacokinetics, and Biologic Activity of Escalating Doses of FG-3019 in Subjects With Incipient Nephropathy Due to Type 1 or Type 2 Diabetes Mellitus |
| Lead sponsor | Kyntra Bio, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | FG-3019 |
| Enrollment | 20 |
| Start date | Jan 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Jan 27, 2005 |
| Last update posted | Dec 12, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: